GSE210591
IL-27 sensitizes immune checkpoint blockade therapy by inducing Treg fragility in high-grade serous ovarian cancer
To characterized the effect of IL-27 on the tumor immune microenvironment in vivo, we selected the subcutaneous tumor-infiltrating CD45+ lymphocytes from tumor in vehicle or recombinant mouse IL-27 treated mice,and performed single-cell RNA sequencing on lymphocytes. Overall design: For mouse subcutaneous xenograft models, HM1 cells (1 × 10^6) were subcutaneously injected into the right flank of B6C3F1 mouse, vehicle or recombinant mouseIL-27 (100 ng per mouse) was injected intratumorally (s.c.) on day of tumor implantation and then every other day thereafter until the end of the experiment. CD45+ lymphocytes were sorted from digested mouse subcutaneous tumor by on day 14 after tumor implantation.